Document is current

Article History

Received: 2 November 2016

Revised: 12 March 2017

Accepted: 20 March 2017

First Online: 10 April 2017

Compliance with ethical standards

:

: The scientific guarantor of this publication is Professor Nandita de-Souza

: The authors of this manuscript declare relationships with the following companies: Alderley Imaging Ltd (Waterton: Director; Stockholder); AstraZeneca (Waterton: Former employee; Stockholder).

: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking () under grant agreement number 115151, the resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. The authors are members of the QuIC-ConCePT Consortium whose participants include: AstraZeneca, European Organisation for Research and Treatment of Cancer (EORTC), University of Cambridge, University of Manchester, Westfälische Wilhelms-Universität Münster, Radboud University Nijmegen Medical Center, Institut National de la Santé et de la Recherche Médical, Stichting Maastricht Radiation Oncology “Maastro Clinic”, VUmc Amsterdam, King’s College London, Universitair Ziekenhuis Antwerpen, Institute of Cancer Research – Royal Cancer Hospital, Erasmus Universitair Medisch Centrum Rotterdam, Imperial College of Science Technology and Medicine, Keosys S.A.S., Eidgenössische Technische Hochschule Zürich, Amgen NV, Eli Lilly and Company Ltd, GlaxoSmithKline Research & Development Limited, Merck KGa, Pfizer Limited, F.Hoffmann - La Roche Ltd, Sanofi-Aventis Research and Development.

: Dr Matthew Orton (The Institute of Cancer Research, London, UK) kindly provided statistical advice for this manuscript.

: Institutional Review Board approval was obtained (UK REC reference 15/LO/0882).

: Written informed consent was obtained from all subjects (patients) in this study.

: • prospective• cross-sectional study• multicentre study